RecruitingPhase 1NCT03326921

HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Studying Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Fred Hutchinson Cancer Center
Principal Investigator
Elizabeth Krakow, PhD
Fred Hutch/University of Washington Cancer Consortium
Intervention
CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR(biological)
Enrollment
24 enrolled
Eligibility
80 years · All sexes
Timeline
20182028

Study locations (1)

Collaborators

HighPass Bio, Inc. · PromiCell Therapeutics, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03326921 on ClinicalTrials.gov

Other trials for Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement

Additional recruiting or active studies for the same condition.

See all trials for Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement

← Back to all trials